RapidGene Insights
Subscribe
Sign in
Home
Contact
Archive
About
FDA Grants Breakthrough Status to Neurogene’s NGN‑401 Gene Therapy: Full‑Length MECP2 Delivery Picks Up Speed
A one‑and‑done AAV gene therapy for Rett syndrome—innovation in transgene regulation meets regulatory privilege.
Feb 28
•
RapidGene
BioNTech’s TNBC Neoantigen mRNA: Big T Cells, Small Timelines
Nature reports durable T-cell immunity in 14 patients — but a 69-day average sequencing-to-release clock is the real product killer.
Feb 19
•
RapidGene
Moderna’s Flu Filing Whiplash: FDA Accepts Amended mRNA-1010 BLA—The Real Cost Moves to Post-Marketing
This isn’t “science winning”—it’s regulatory risk reallocation.
Feb 18
•
RapidGene
EU Greenlights Moderna’s mNEXSPIKE: Same Vaccine Category, Smaller mRNA Payload, Lower Dose
This isn’t a delivery revolution—it’s a pragmatic industrial optimization: truncate the antigen, cut the dose, and buy back capacity, tolerability, and…
Feb 18
•
RapidGene
V940/mRNA-4157 at 5 Years: Personalized mRNA Oncology Survives the Durability Test
The science is maturing. The real bottleneck is still personalized manufacturing.
Feb 18
•
RapidGene
NeoVac’s “NeomiVac” Moment: LNP 2.0 Finally Touches Humans
First-in-human tolerability claims are the real gate—because chronic dosing dies in the lipid shell, not the mRNA.
Feb 18
•
RapidGene
Moderna’s Flu Flop & Alnylam’s Enzymatic Empire: A Tale of Two RNAs
Beyond the headlines—why a "Refusal-to-File" signals a regulatory crackdown on mRNA shortcuts, while RNAi quietly solves the manufacturing bottleneck.
Feb 15
•
RapidGene
The Spiral Ascent: Why We Launch RapidGene Insights Now
Beyond the recent FDA headwinds—tracking the convergence of AI, Nucleic Acid Therapeutics, and Unmet Patient Needs.
Feb 15
•
RapidGene
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
